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Abstract 
Objectives: The International Society for Bipolar Disorders (ISBD) Big Data Task Force 
assembled leading researchers in the field of bipolar disorder (BD), machine learning, and 
big data with extensive experience to evaluate the rationale of machine learning and big data 
analytics strategies for BD.  
Method: A task force was convened to examine and integrate findings from the scientific 
literature related to machine learning and big data based studies to clarify terminology and to 
describe challenges and potential applications in the field of BD. We also systematically 
searched PubMed, Embase, and Web of Science for articles published up to January 2019 
that used machine learning in BD. 
Results: The results suggested that big data analytics has the potential to provide risk 
calculators to aid in treatment decisions and predict clinical prognosis, including suicidality, 
for individual patients. This approach can advance diagnosis by enabling discovery of more 
relevant data-driven phenotypes, as well as by predicting transition to the disorder in high-
risk unaffected subjects. We also discuss the most frequent challenges that big data 
analytics applications can face, such as heterogeneity, lack of external validation and 
replication of some studies, cost and non-stationary distribution of the data, and lack of 
appropriate funding.  
Conclusion: Machine learning based studies, including atheoretical data-driven big data 
approaches, provide an opportunity to more accurately detect those who are at risk, parse-
relevant phenotypes as well as inform treatment selection and prognosis. However, several 
methodological challenges need to be addressed in order to translate research findings to 
clinical settings.  
Keywords: bipolar disorder, big data, machine learning, deep learning, data mining, 
personalized psychiatry, risk prediction, predictive psychiatry. 
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Introduction  
Bipolar disorder (BD) has a worldwide prevalence of about 2% with subclinical 
variants affecting another 2% of the population.1 According to the World Health 
Organization, BD is among the top 10 leading causes of disability-adjusted life years in 
young adults.2 Rates of completed suicide in patients with BD are 7.8% in men and 4.9% in 
women.3 These patients commonly endure prolonged periods of trial and error before an 
effective treatment among the possible options is found. Although interventions to treat and 
prevent mood episodes are available and detailed in Guidelines,4,5 unselected treatment or 
guideline drive treatment is frequently suboptimal, and about 60% of the patients relapse into 
depression or mania within two years of treatment initiation.6,7 Early intervention is critical in 
BD to prevent progression and complications such as suicide attempts,8–10 however, current 
approaches to diagnosing BD leave room for improvement, since there is an average delay 
of ten years between the first symptoms and a formal diagnosis.11 
Randomized clinical trials (RCTs) and meta-analyses have helped to find effective 
treatments for BD, such as lamotrigine12 and quetiapine,13 by using traditional statistical 
methods, which primarily provide average group-level results based on measures of central 
tendency and variance. This approach allows us to make broad generalizations about 
patients with BD in regard to specific treatments. However, it fails to detect nuances related 
to an individual patient, and significant results may not represent a real benefit for 
individuals.14 Indeed, subjects included in clinical trials do not consistently reflect patients 
with BD from real-world clinical scenarios – in fact, the very idiosyncrasies that characterize 
most of these patients, such as the multi-morbidity profiles, are often exclusion criteria in 
clinical trials.15 In addition, evidence suggests that BD is a heterogeneous disorder with valid 
subgroups, each with a specific responsiveness to prophylactic treatment.16,17 Big data 
analysis by machine learning techniques provides the means to move beyond group level 
statistics into individual subject classification based on accuracy, sensitivity, specificity, and 
area under the ROC curve (AUC). 
Another elusive goal in the current study of BD is the prediction of prognosis in 
individuals already affected and transition to full-blown illness in those ones at risk.18 The 
linear association between risk factors and clinical outcomes is important to understand 
BD,19 however, they do not objectively stratify which subjects will develop BD or, when 
affected, what will be their prognosis.20,21 The integration of a huge number of risk factors 
necessarily requires new analytical tools. To fill these gaps, big data analytics is being used 
in psychiatry to provide predictive models for both clinical practice and public health 
systems.22 
In this manuscript, the Big Data Task Force of the International Society for Bipolar 
Disorder (ISBD) will explore the role of machine learning techniques and big data in 
improving outcomes prediction in prevention, diagnosis, and treatment of individuals with 
BD. Specifically, we will 1) define big data and machine learning techniques and outline the 
issues that need to be considered in machine-learning-based studies; 2) update a 
systematic review of published studies on machine learning and big data in BD to illustrate 
where the field is at right now; and 3) identify the obstacles for application of these 
methodologies in BD and propose strategies to overcome them. 
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Methods 
 A Task Force was convened to examine, discuss, and integrate findings from the 
scientific literature related to machine learning based studies and big data to clarify 
terminology and to describe challenges and potential applications in the field of BD. We also 
updated a systematic review published by our group.23 
 
Search strategy 
 For the systematic review, we searched PubMed, Embase, and Web of Science for 
articles published between January 1960, and January 2019 by using the following 
ke wor s: (“B    ata” O  “ rt     al Intell  en e” O  “Ma h ne  earn n ” O  “ auss an 
 ro ess” O  “Cross- al  at on” O  “Cross  al  at on” O  “Cross al  at on” O  “ e ular ze  
lo  st  ” O  “  near   s r m nant anal s s” O  “   ” O  “ an om  orest” O  “Na  e Ba es” 
O  “ east   solute sele t on shr nka e o erator” O  “elast   net” O  “    O” O  “ VM” 
O  “rele an e  e tor ma h ne” O  “ attern re o n t on” O  “Com utat onal Intell  en e” 
O  “Com utat onal Intell  en es” O  “Ma h ne Intell  en e” O  “Knowle  e 
 e resentat on” O  “Knowle  e  e resentat ons” O  “su  ort  e tor” O  “ VM” O  
“ attern  lass    at on”)  N  (“B  olar   sor er” O  “B  olar   sor ers” O  “Man  -
 e ress  e  s  hos s” O  “Man    e ress  e  s  hos s” O  “B  olar    e t  e  s  hos s” 
O  “Man  - e ress  e  s  hoses” O  “Man a” O  " O  “Man    tate” O  “Man    tates” 
O  “B  olar  e ress on” O  “Man     sor er” O  “Man     sor ers” O  “B  olar euth m  ”). 
We also searched the reference lists to find potential articles to include. There were no 
language restrictions. 
 
Eligibility criteria 
 This systematic review was performed according to the PRISMA statement.24 Articles 
met the inclusion criteria if they assessed patients with BD using machine learning 
techniques. Technical and theoretical studies that used machine learning techniques but did 
not assess patients with BD were excluded. We also excluded studies that included only 
individuals below 18 years of age. 
 
Data collection, extraction, and statistical analysis 
 Two researchers (DLG and PB) independently screened titles and abstracts of the 
identified articles. They also obtained and read the full texts of potential articles, supervised 
by ICP who made the final decision in cases of disagreement. Data extracted from the 
articles included year of study publication, data used in the machine learning model (i.e., 
neuroimaging, blood biomarkers, clinical and demographical characteristics, among others), 
sample size, diagnoses assessed in the study, machine learning algorithm, and statistical 
measure of performance (i.e., accuracy, sensitivity, specificity, area under the curve, true 
positive, false positive, true negative and false negative). When this data was not available, 
we requested it from the authors. 
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Definitions 
Big Data  
The first definition of big data focuses on the 3 Vs - velocity, volume, and variety. 
“Velocity” refers to the speed at which the  ata  s  enerate   wh le “Volume” refers to the 
amount of data, and is readily demonstrated by for example the storage space needed. 
“Variety” refers to the diverse nature of data collected from many sources. For healthcare, 
this means that data for understanding one's behaviour should not be collected only from 
anamnesis, exams, and clinical questionnaires. Instead, data should be pervasive and 
gathered in multiple modalities, including patient behavior and social relationships. A more 
recent definition adds veracity and value as two additional Vs.25 “Veracity” concerns whether 
or not we  an trust the  ata we  ather  an  “Value” refers to the fact that we must integrate 
all of the aforementioned pillars of big data towards improvement on how we treat and 
monitor patients, thus generating value for families, caregivers, and patients suffering from 
the BD.26 
One example of a big data application is ecological momentary assessment, which 
refers to the continuous collection of data by smartphones or personal devices. Its potential 
is based on the assumption that traditional clinical approaches in assessment of mood 
symptoms are unsatisfactory since they require that the patient summarize their symptoms 
over a defined time framework (e.g. one month) in one sentence:  Over the past month I felt: 
”goo ”  “not so  oo ”  “ er   e resse ”  or “a l ttle   t man  ”.  herefore, there is no 
granularity in mood reporting and no reliable information about variability or association with 
other symptoms or exposures, which would be putatively more in line with neurobiology. 
Additionally, there is no ecological validity to this kind of reporting (patients behave 
differently when they are in our offices). We need a comprehensive, ecologically valid, 
precise and passive collection of data as proposed in some studies.27,28 However, such rich 
data collection will generate millions of data points that will require specific approaches for 
analysis.  
 
Machine Learning 
Most of the process for finding useful patterns in data that have translational meaning 
and can be incorporated in day-to-day practice is possible through machine learning 
approaches - a powerful tool for pattern recognition and responsible for most of the recent 
advances in artificial intelligence. Through almost no pre-assumptions and a nonlinear 
function canvas, we can model complex patterns that can identify relationships between 
large amounts of and diverse data.29 This change in perspective introduces more flexibility in 
our groups (we may include fewer constraints in inclusion/exclusion criteria from clinical 
trials), while providing important information on a clinical outcome by taking into account 
heterogeneity. Furthermore, by incorporating feature selection in the process, we can 
automatically select subgroups of predictors that are most relevant for a model, providing 
simpler and more clinically useful results.30 
But how does machine learning operate? Usually, machines receive data from a 
certain scenario, ranging from simple online surveys responses to complex biomarkers 
measurements, such as genetics or neuroimaging, and approximate a function that best fits 
the predictors.31 This process is called training and it represents the process of learning. In 
the context of healthcare, the learning method is usually contained in one of two paradigms, 
supervised or unsupervised learning. In supervised learning, the user feeds the machine 
with predictors and expected outcome. The machine thus learns a mapping     from the 
predictor space   to the outcome space  . This paradigm includes tasks such as predicting 
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suicide attempts in patients with mood disorders based on prior clinical or demographic 
variables.32 However, unsupervised learning does not depend on   and has clustering as its 
most common class of algorithms. Clustering can find hidden groups underlying the 
 re   tors’ variance and help users explain phenomena. This type of learning includes 
finding subgroups of patients that share underlying characteristics, such as suicidaity or 
neurocognitive impairment in a proportion of patients with BD.33 
To make easier the transition for practitioners to the lingo introduced in this new field, 
we provide a quick terminology reference in Table 1. Additionally, Table 2 provides important 
points to be considered in machine-learning-based studies and Figure 1 shows how a 
machine learning experiment should be conducted. It is important to note that machine 
learning is but one of several methods that can be used to analyze big data. For instance, 
discriminant analysis or various methods of principal component analysis, cluster analysis, 
factor analysis can all be used with various assumptions being met for analyzing large data 
sets and for differentiating either pre-defined groups ("supervised") or hypothesis-free (data-
generated) subgroups ("unsupervised"). We chose machine learning techniques in the 
present review because of its ability to model complex patterns, including non-linear 
relationships. 
 
How will machine learning and big data analytics contribute to the field of bipolar 
disorder?  
 We found 1124 potential abstracts and included 91 articles in the present review, 
with one of these added after reference screening (Figure S1). We found 37 additional 
articles compared to the prior systematic review.23 We briefly described below how machine 
learning and big data will contribute to the field of BD by highlighting some of the included 
articles. The most relevant characteristics and findings of each of the 89 included studies are 
described in the supplemental material (tables S1, S2, S3, and S4). 
 
Diagnostic studies 
 Structural and functional neuroimaging, as well as diffusion tensor imaging (DTI), 
have been widely used in classification studies.34–36 A recent large study applied support 
vector machines to MRI data (regional cortical thickness, surface area, subcortical volumes) 
from 853 patients with BD and 2167 control participants from 13 cohorts in the ENIGMA 
consortium.37 Authors found an AUC of 0.71 in differentiating BD from controls. Additionally, 
a recent meta-analysis showed an AUC of the summary ROC curve of 0.70 for structural 
and of 0.75 for functional neuroimaging studies.23 We found one study that used DTI and 
included 67 unmedicated depressed patients, including 31 patients with BD and 36 with 
major depressive disorder (MDD). Authors found that the fractional anisotropy (FA) tract 
profile of the left anterior thalamic radiation can be used to differentiate between the BD and 
MDD patients at an accuracy of 68.33%.38 Other sets of data, such as genetics,39–44 
electroencephalogram,45–50 neuropsychological tests,51,52 blood biomarkers,28,53–56 text,57 
facial expressions,58 and speech59 were also used to classify patients with BD from healthy 
controls or from other psychiatric disorders (Table S1). It is worth mentioning that a study 
used the concept of ecological momentary assessment to distinguish patients with BD from 
patients with borderline personality disorder and healthy controls by using daily mood ratings 
from a smartphone app.60 Authors reported that the methodology classified 75% of 
participants into the correct diagnostic group compared with 54% using standard 
approaches. 
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 These studies may provide a more objective diagnosis for BD in the near future. 
However, some limitations should be addressed to allow translation of these findings to the 
clinical practice. First, the initial AUC of the predictive models should be improved by 
including other layers of data and applying a multimodal data approach. Second, most of the 
studies lack external validity since they were built by using only patients with BD and 
controls. Therefore, population and largely representative studies, including other psychiatric 
or neuropsychiatric disorders, should be conducted to ensure generalization of the proposed 
models. Third, we still do not know how these models will perform in face of patients from 
different stages of the disorder.8,15,61 In this sense, a recent study found that a machine 
learning model developed by using the relevance vector machine algorithm and white matter 
from structural MRI was more accurate in identifying patients with BD at the late stage.62  
 
Prediction of poor clinical outcomes  
Some studies used machine learning techniques to predict suicidality and mood 
episode relapse. A study tested a set of machine learning algorithms coupled with clinical 
and demographic variables to develop a clinical signature of suicidality in 144 patients with 
mood disorders, including BD.63 The study reported a balanced accuracy of 72% and an 
AUC of 0.77 in predicting suicide attempts. Prior hospitalizations for depression, comorbid 
post-traumatic stress disorder, cocaine dependence, and history of psychotic symptoms 
were the most robust variables in the model. Other studies also predicted suicidality by using 
machine learning coupled with a combined genomic and clinical risk assessment approach 
and built models with an AUC of 0.9864 and 0.8265 in patients with BD. It is also worth 
mentioning that a recent text classification study used letters and diaries of Virginia Woolf to 
identify written patterns associated with suicide.66 Authors found an AUC of 0.80 and a 
balanced accuracy of 80.45% by using Naïve-Bayes machine-learning algorithm.  
Another study used demographic and clinical features, including follow-up variables, 
to assess depression relapse in 108 patients with BD and achieved an accuracy of 85%, and 
a sensitivity of 92%.67 Furthermore, a study using voice features collected in phone calls to 
 lass     at ents’ a  e t  e states  a h e ed an AUC of 0.78 (depressed vs. euthymic) and 
0.89 (manic/mixed vs. euthymic).68 These proof-of-concept and experimental protocols 
 llustrate ma h ne learn n ’s  otent al to a    n the  l n  al assessment o  BD patients, 
yielding models with sufficient accuracy to monitor mood states in real time which may help 
assess disease activity and advance early intervention. Although promising, most of these 
studies included small samples, and, therefore, need to be interpreted with caution requiring 
adequate model validation in different settings and populations. Table S2 in the 
supplemental material presents studies that used machine learning methods to predict 
clinical outcomes in BD.   
 
Selection of treatment 
The incorporation of tools from machine learning to guide trials for better-tailored 
interventions is a necessary next step to move beyond current group-based approaches.69 
These models can be displayed as user-friendly calculators, and incorporated into the 
clinical workflows of electronic medical records.70 For instance, if a calculator predicts that a 
given patient is unlikely to respond to an intervention, the clinician could then consider 
alternatives.71 Accordingly, patients would benefit from more precise treatment plans with 
less delay avoiding the associated burden of untreated illness. These calculators estimate 
the probability of a particular outcome and are ideal for assessing the multimorbidity profile 
and other nuances found in patients with BD - as long as their heterogeneity is represented 
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in the training dataset.69 In the field of BD, a pilot study developed a treatment response 
calculator for lithium.72 Authors included 20 subjects with first-episode bipolar mania who 
received lithium over 8 weeks. A machine learning model coupled with fMRI and 1H-MRS 
scans data at baseline pretreatment was trained and validated. The model was able to 
predict post-treatment symptom reductions at 8 weeks with 80% accuracy in the validation 
phase. 
Machine learning guided interventions will not only facilitate the selection of treatment 
based on efficacy but also aid in the prevention of side effects.69 In this sense, a study with 
more than 5700 patients undergoing lithium treatment built a predictive algorithm to renal 
insufficiency by using logistic regression and electronic medical records.73 Authors found an 
AUC of 0.81 in an independent testing set. Use of lithium more than once daily, lithium levels 
greater than 0.6mEq/l, and the use of first-generation antipsychotics were independently 
associated with risk. These findings suggest that risk stratification can be expanded to other 
treatments and interventions. Moreover, estimating the risk of certain side effects could allow 
more informed decisions and facilitate the development of prevention strategies.  
Finally, machine learning guided trials may have a different design compared to 
RCTs.69 First, it is not necessary to have a control group since the aim is to stratify the 
already known evidence from RCTs among patients with BD. Second, inclusion criteria 
should not be restrictive since the heterogeneity, multimorbidity profile and other nuances 
found in patients with BD from real-world clinical scenarios should be represented in the 
sample. These types of trials will shift the focus from group-level averages to individuals and 
will ultimately leverage each person’s un  ue clinical and biological profile to improve 
selection of treatment. Table S3 shows machine learning studies predicting treatment 
response and adverse effects.72–76 
 
Prediction of transition to bipolar disorder  
Another elusive goal in the field of BD is the prediction of transition to full-blown 
illness and its prognosis. The risk to first degree relatives of a patient suffering from BD is 
estimated at 10-fold that of the general population.77 Additionally, several risk factors for 
bipolar and related mood disorders have been identified in those at confirmed familial risk 
including the presence of subthreshold mood symptoms (hypomanic, depressive and anxiety 
symptoms),61,78–80 antecedent non-mood childhood diagnoses (i.e., anxiety and sleep 
disorders)81, experiences of childhood abuse and neglect,82 increased exposure to unstable 
parental BD83 and temperament factors.84 However, the relative contribution of these 
independent risk factors and the interaction among them in predicting mood disorders is 
unclear. In addition, it is unlikely that a single biomarker can predict who will develop BD 
since multiple and complex bio-psychosocial pathways lead to these disorders.85 However, 
no study has used machine learning techniques to predict conversion to BD in those at 
identified risk as yet. Two studies have built risk calculators for illness development using 
other mathematical approaches. One of these assessed the probability that an offspring of a 
parent with BD will develop a new-onset bipolar spectrum disorder within the next 5 years.79 
Authors found an AUC of 0.76 by using Cox proportional hazards regression. Another similar 
study built a risk calculator to predict the individual risk of transition from subthreshold 
bipolar symptoms to bipolar I or II in youth and reported an AUC of 0.71.86 
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Data clustering using unsupervised and semi-supervised machine learning 
 BD and other psychiatric disorders are all extremely heterogeneous, in terms of their 
 l n  al  resentat on (wh  h we re er to as ‘ l n  al hetero ene t ’)  un erl  n    olo   al 
 auses (‘  olo   al hetero ene t ’) an  en  ronmental exposures (‘en  ronmental 
hetero ene t ’). These sources of heterogeneity remain a substantial barrier to better 
understanding the causative mechanisms of psychiatric disorders and to developing optimal 
treatments and diagnostic tools. It has long been recognized that we must look beyond 
simple case-control comparisons to be able to deconstruct the heterogeneous phenotype of 
BD.87 Unsupervised and semi-supervised machine learning techniques may aid to digest the 
heterogeneity; however, few studies used these techniques in the field of BD (Table S4).88–92 
In addition, replication remains a major challenge for these approaches. Indeed, none of the 
studies we have reviewed have been independently replicated. 
 
Obstacles and ethical issues 
 Although we have a plethora of studies using machine learning and big data 
approaches to tackle complex questions in BD, knowledge translation to clinical practice is 
still under-developed93. Obstacles, including model validation, computational power, 
multimodality, assessment of rare events, cost and non-stationary distribution of the data, 
heterogeneity both phenotypically and etiologically, phenomenological diagnosis, lack of a 
uniform pipeline for machine learning studies, lack of appropriate funding, and lack of 
interpretability, need to be addressed. 
 
Model Validation 
When training a model, machines can either fit the training data incredibly well or not 
find a function that suits the data properly. In the former, we should be careful whether the 
machine is not performing overfitting. In that case, when performing inferences on new data 
(unseen during the training process), the machine will probably lead to suboptimal results. In 
the latter case, when the machine underfits the data, it can be easily seen during training. 
Most of the time we refer to such challenge as a variance and bias tradeoff. Essentially, the 
goal is to develop a model with enough variance to model complex shapes but not too much 
to overfit the data.  
An additional point related to overfitting is that it can also lead to false conclusions on 
data behavior. By observing the variables that contribute to the result, the researcher could 
wrongfully declare a new finding for an outcome not able to be replicated in another trial. For 
that reason, one must follow a protocol to ensure that the findings are robust. There are 
several approaches here, including Bootstrap, Cross-Validation, and Holdout.94 The gold 
standard is debatable but usually consists of performing Cross-Validation to find the best 
fitting model in the training data and finally evaluating once in a Holdout set. The Holdout set 
should be totally unseen during the process and ultimately should be collected on an entirely 
new sample at a different institution when possible. 
 
Computational Power and Quality of Data  
 There is a clear tradeoff between how much data you have and the quality of the 
models you can develop. Usually, the more data you gather, the more your model will 
generalize for unseen instances. Additionally, you lessen the chances of overfitting and it 
gets easier to properly use the validation protocols. Two other facets of machine learning 
research in healthcare are challenging. First, collecting large amount of data can be costly 
and often associated with  logistical challenges.  Second, the computational power required 
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to address large databases grows exponentially with the data complexity/size. Performing 
proper feature selection and hyperparameter optimization in big data can also be 
challenging.30 Some studies on unstructured data such as images, text, video, and others, 
can also approach the problem of using deep learning. Convolutional neural networks, the 
standard framework for systems in this kind of data, depend on dedicated graphic cards to 
train due to computational requirements. Computers that can train such models are not 
widely available for researchers and purchasing capable computers adds a significant cost 
to the experiments. 
 It is important to emphasize the need to share and harmonize data. It is crucial to 
have good quality data, to handle missing data adequately, and to utilize at least few 
instruments in common and apply them similarly across sites. These strategies will not only 
facilitate the task of building big datasets but also allow replication of positive findings. 
Another important point regarding BD is the assessment of rare events, such as suicide. 
Because of statistical rarity of suicide deaths in the short term, even models with good 
accuracy would result in a poor risk stratification tool.95 In this case, resampling strategies 
should be applied in the training phase. 
 
Multimodality 
Working with multimodal data can provide another challenge. There is no standard 
way of integrating information from multiple sources, such as using both text and image for 
predicting an outcome. By using features extracted from each modality, the model could 
possibly use the data, but this kind of approach usually diminishes the potential of 
information that could be extracted. This happens because feature extraction algorithms 
most of the time depend on human knowledge, decreasing the potential for data-driven 
approaches to find hidden patterns. 
However, deep learning poses a possible solution for such task. By learning the 
feature extraction process, deep learning models tend to properly find most of the important 
information for solving the task. This includes finding the potentially hidden patterns that 
could be used for clinical practice or leveraging our knowledge on a disorder. To handle 
multimodal data, the models learn a joint latent space where semantically similar data from 
any of the modalities presented are close.  
This type of analysis does not come without drawbacks. By performing analysis on 
raw data, deep learning is very susceptible to domain shift. By training with almost no 
preprocessing, the data can follow very different distributions when varying equipment. A 
good example could be the range of distributions that the same slice of a brain scan can 
assume based on which MRI protocol and equipment was used. When changing modalities 
such as MRI or CT, the distribution shifts even more drastically, generally completely 
invalidating using the model without further training. For that reason, when deploying for 
clinical practice, the researchers should be careful to guarantee that the scenario in which 
the model is being applied follows the same distribution from the training data. If this is not 
maintained, there is no way to assure a good predictive performance. 
 
Non-stationary distribution of the data 
Researchers should be careful with non-stationary distributions to use their models. 
These are cases where the data distribution changes over time, and thus the moment in 
which the data was collected heavily influences the model's behavior. An example could be 
a model to predict suicide attempts in patients with BD through their posts in social media. In 
that case, the relationship between the words and suicide attempts may change in part 
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because the writing style shifts over time. This is one of the most challenging problems in 
machine learning, as the variables that could impact the model’s predictive power are most 
of the time hidden from our perspective. This also happens very often in companies trying to 
bring machine learning to production. A real case in healthcare research dates back to 2009 
when a model trained for predicting flu epidemics was found by 2011 to consistently 
overestimate flu prevalence in subsequent years.96,97 
 
Heterogeneity and phenomenological diagnosis 
 Current  s  h atr     a nos s  s  ase  on  l n  al ju  ment o   at ent’s narrat  es an  
behavior. Specifically, BD illustrates the dilemma of diagnostic systems solely based on 
clinical judgment. Clinical observations are subjective in nature, often incomplete, and prone 
to inconsistencies between evaluators. This scenario hampers the training process in 
machine learning studies since both outcomes and predictors may be subject to these 
inconsistencies. As abovementioned, heterogeneity could also complicate this scenario. 
Also, machine learning, almost by design is suited better for detection of aggregates of 
multiple small effects. This could be the underlying reality of psychiatric disorders, but it 
could be also a "diluting effect" of heterogeneity.98 
 
Funding agencies and lack of interpretability 
 Due to their disruptive nature, data-driven approaches are still encountering some 
acceptance barriers in the healthcare community. Unlike other fields, such as computer 
science, there is no clear consensus among researchers as to whether such methods are 
reliable. The main concern is that not fully depending on hypothesis leads to fishing 
expeditions, and thus the risk of false positive findings. Funding agencies, consequently, are 
still concerned and conservative in their investment in such approaches. This will probably 
be overcome as the machine learning protocols for healthcare become more widespread, 
and the results are more convincing. 
Yet another concern about such approaches is the lack of interpretability that the 
resulting models usually possess. There is no clear way of interpreting complex non-linear 
models. However, if a phenomenon is presented in a non-linear pattern, the ability to model 
its function surpasses the need for understanding its behavior. In many clinical applications, 
it can be expected that the clinician does not need to fully comprehend how the machine is 
processing information. In that case, the main concern is how effectively the model can 
predict a specific outcome. Although visualization and interpretation are important, perhaps 
we should not be too limited by human capabilities of pattern recognition, and instead, be 
open and interested in how we can improve practice using proven and reliable predictions. 
 
Ethical issues 
 Big data analytics and machine learning do not come without ethical worries. First, 
regarding the privacy and anonymity of the data.99 Hospitals and institutions need to 
establish clear policies to determine who is granted access to collected information, to avoid 
sensitive data to be inadequately exposed and analyzed. At the same time, it is our opining 
that the lack of data sharing is one of the main obstacles, which hinders the full realization of 
the potential of machine learning. Without large sample sizes and multi-site data, it will not 
be possible to build reliable machine learning algorithms applicable to heterogeneous 
psychiatric disorders. Thus, developing ethico-legal framework, which would facilitate safe 
data sharing is a key and critical component of the machine learning field. The cost of data 
sharing to participant needs to be carefully weighted against the potential benefits to this 
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approach to the society. In case of brain imaging data, for instance, the benefit of data 
sharing, which could yield new diagnostic/prognostic tools, markedly outweighs the risk to 
the participant whose anonymized data are shared. 
 Second, the impact those predictive models may have for individuals. If we can 
predict that a patient with BD will have a more pernicious illness course, that would mean he 
will make more use of health services, and therefore, may be charged more for a health 
plan. The argument that subjects identified as at risk of suicide, for instance, could suffer 
psychosocial prejudice is indeed a major concern,95 however, this issue can be in part 
handled by fostering medical confidentiality, which is possible provided that these subjects 
are not at acute risk of suicide. Additionally, if an individual is predicted to develop bipolar 
disorder or attempts suicide, how this information influences his quality of life? How will it 
influence his relationships with his peers? It is possible that the stressful burden of knowing 
may incur in speeding the disorder installment or even lead to another disorder, such as 
substance abuse. An important question, therefore, is how our patients may cope with such 
predictions about their future, and weigh harm and benefit of its use. Future guidelines in the 
field of bipolar disorder may have to address the  ro lem o  “ otent al  at ents” not only in 
terms of therapeutic preventive strategies but also in terms of how to handle the harm 
related to this prediction. 
 
Conclusion  
The high morbidity and mortality related to BD provides the impetus for research into 
more sophisticated computational approaches for risk prediction, individualized treatment, 
and prognosis. In this manuscript, we summarized how machine learning techniques and big 
data analysis may help the field by providing predictive models at the individual level. It is 
important to note that some of the studies included used machine learning techniques but 
not big datasets. Additionally, some of the most intriguing results derive from small studies 
that have yet to be independently replicated. The field of machine learning and big data in 
BD is still in its infancy and replication of the findings is required. However, technology made 
available by machine learning and big data analytics gives us the unique opportunity to study 
the “real  at ent” and all of the inherent complexity.100 It is also important to mention that in 
universal health systems, a wealth of untapped and yet available, person-specific 
information is attached to every single patient and could be used to build diagnostic tools. 
Currently, the full scope of individual information is under-utilized and the information value 
of the sequence and timeframe of events is underdeveloped. Until recent times one major 
constraint for the use of such wealth of information was the lack of means to analyze it in a 
coherent way with standard statistical techniques. The emerging field of big data and 
machine learning provides a framework to deal with such broad and complex datasets in 
real-time to advance our understanding and treatment of BD.  
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Table 1. Important terms and their respective definitions 
Term Definition 
Double Dipping Circular analysis of the test data set. The researcher uses the test data 
twice, overestimating the predictive power 
Overfitting Model too adjusted to the training set. This leads to problems of 
generalization 
Underfitting Model not well adjusted to the data. This usually implies that a more 
complex model is required 
Feature Selection Selecting the most important predictors, either by domain experts or in a 
data-driven manner 
Hyperparameter 
Tuning 
Model induction algorithms usually rely on hyperparameters. These are 
chosen by the user and can be optimized for better results 
Kernel Kernel  s a wa  o   om ut n  the  ot  ro u t o  two  e tors “x” an  “ ”  n 
some (possibly very high dimensional) feature space. Kernel methods 
are a class of algorithms for pattern analysis, whose best-known 
member is the support vector machine 
Internal Validity Validating results in the same context (data from the same trial, 
institution, and others) 
External Validity Validating results from different contexts. This shows that the model is 
able to handle other scenarios (different trials, institutions, and others) 
Multimodal Data Combining data from multiple heterogeneous sources. This includes 
combining text, audio, video, and others. 
Unstructured 
Data 
Data that does not follow a specific organization, such as text and 
images. 
Curse of 
dimensionality 
When multiple features are present, separating data in the 
multidimensional space becomes easier. Consequently, overfitting data 
is a common occurrence. 
Holdout Subset of the data that is kept away from the analysis for posterior 
testing. 
Cross-validation Validation protocol that involves splitting data into k-folds to verify if the 
model is able to generalize from training 
Bootstrap Alternative validation protocol that creates multiple randomized subsets 
of training data 
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Table 2. Important points to be considered in machine-learning-based studies. 
 
Methodological feature Considerations 
Representativeness of the 
sample 
 
Was the study truly representative of the target 
population heterogeneity or included a selected 
group of users? 
In the case of supervised 
machine learning studies, 
the subjects in different 
groups are comparable 
based on the study design 
or analysis.  
Did the study control for the most important 
confounding factors? 
 
Assessment of the outcome Independent blind assessment, medical record or 
self-report? 
Machine learning approach Was the machine learning algorithm used to 
analyze data clearly described and appropriate? 
Were metrics of performance presented? 
Class Imbalance How did authors address the class imbalance 
problem? 
Test Dataset Was the test dataset "unseen"? 
Feature Selection and 
Hyperparameter Tuning 
Did the study describe both feature selection and 
hyperparameter tuning? 
 
Missing Data Did the study describe how authors handled missing 
data, including if they were inputted or removed? 
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Figure 1. Essential steps to conducting machine learning models. A) The patient data 
comes from multiple sources and biological levels. B) The most important features should be 
selected in order to reduce the dimensionality of the problem. This step is done mainly in two 
different forms. One way is through feature selection algorithms that automatically extract 
information (data driven). The other is by domain experts that identify which features should 
be kept through their knowledge on the subject (hypothesis driven). C) Candidate models 
generated by the induction algorithm. D) Final model chose from the candidate pool by a 
performance metric, such as the area under the ROC curve or accuracy. E) Model validation 
with external data, potentially from different institutions to avoid bias. F) Translate the 
knowledge to generate risk calculators.  
